摘要:
The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
摘要:
The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
摘要:
There is provided antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages, and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease.
摘要:
The invention relates to an antibody or fragment thereof that is capable of specifically binding to and blocking TREM-1, wherein the antibody or fragment thereof is capable of blocking PGLYRP1-induced activation of TREM-1; wherein the antibody or fragment thereof comprises: a CDRH1 sequence corresponding to amino acid residues 31 to 35 (TYAMH) of SEQ ID NO: 6, wherein one of these amino acid residues may be substituted by a different amino acid residue; and/or a CDRH2 sequence corresponding to amino acids 50 to 68 (RIRTKSSNYATYYAASVKG) of SEQ ID NO: 6, wherein one, two or three of said amino acids may be substituted with a different amino acid residue; and/or a CDRH3 sequence corresponding to amino acid residues 101 to 110 (DMGQRRQFAY) of SEQ ID NO: 6, wherein one, two or three of said amino acid residues may be substituted by a different amino acid;
and wherein the antibody or fragment thereof comprises: a CDRL1 sequence corresponding to amino acid residues 24 to 38 (RASESVDTFDYSFLH) of SEQ ID NO: 7, wherein one, two or three of these amino acid residues may be substituted with a different amino acid; and/or a CDRL2 sequence corresponding to amino acid residues 54 to 60 (RASNLES) of SEQ ID NO: 7, wherein one or two of these amino acid residues may be substituted with a different amino acid; and/or a CDRL3 sequence corresponding to amino acid residues 93 to 101 (QQSNEDPYT) of SEQ ID NO: 7, wherein one or two of these amino acid residues may be substituted with a different amino acid
摘要翻译:本发明涉及能够特异性结合并阻断TREM-1的抗体或其片段,其中所述抗体或其片段能够阻断PGLYRP1诱导的TREM-1活化; 其中所述抗体或其片段包含:对应于SEQ ID NO:6的氨基酸残基31-35(TYAMH)的CDRH1序列,其中这些氨基酸残基中的一个可以被不同的氨基酸残基取代; 和/或对应于SEQ ID NO:6的氨基酸50-68(RIRTKSSNYATYYAASVKG)的CDRH2序列,其中所述氨基酸中的一个,两个或三个可以被不同的氨基酸残基取代; 和/或对应于SEQ ID NO:6的氨基酸残基101-110(DMGQRRQFAY)的CDRH3序列,其中所述氨基酸残基中的一个,两个或三个可以被不同的氨基酸置换; 并且其中所述抗体或其片段包含:对应于SEQ ID NO:7的氨基酸残基24至38(RASESVDTFDYSFLH)的CDRL1序列,其中这些氨基酸残基中的一个,两个或三个可以被不同的氨基酸置换; 和/或对应于SEQ ID NO:7的氨基酸残基54至60(RASNLES)的CDRL2序列,其中这些氨基酸残基中的一个或两个可以被不同的氨基酸置换; 和/或对应于SEQ ID NO:7的氨基酸残基93至101(QQSNEDPYT)的CDRL3序列,其中这些氨基酸残基中的一个或两个可以被不同的氨基酸置换
摘要:
The current invention relates to a construct, a polynucleotide that encodes said construct and a cell that expresses said construct. Furthermore, the current invention relates to the use of said construct for the treatment of bleedings and their associated co-morbidities and to a method of treatment of bleedings, inflammation and metastasis of cancer cells.